Navigation Links
Dyadic International Upgraded By OTC Markets To "Current Information" Tier
Date:1/23/2013

JUPITER, Fla., Jan. 23, 2013 /PRNewswire/ -- Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries, announced today that it has been upgraded by OTC Markets to "Current Information" which is the highest trading tier on the OTC Pink marketplace. The disclosures required for this upgrade have been posted on the OTC Markets website (www.otcmarkets.com) under Dyadic's ticker symbol, "DYAI."

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and CEO, Mark Emalfarb , stated, "Completion of the upgrade to OTC Pink Current Information is one of several positive steps Dyadic has taken to strengthen our stockholder base and build stockholder value by providing greater transparency through periodic press releases and quarterly and annual disclosures, financial statements and investor conference calls. The confidence and protections provided by these additional disclosures contribute to the significantly greater liquidity of the OTC Pink Current Information Tier as compared to the prior tier assigned to Dyadic."

The Current Information Tier applies to reporting companies that submit filings to regulators with powers of review and that make the filings publicly available and non-reporting companies that make current information publicly available on the OTC Disclosure and News Service pursuant to OTC Markets Guidelines for Providing Adequate Current Information. Disclosures are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.  Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
3. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International Reports 2012 Third Quarter Financial Results
8. 12th U.S. Patent Issued To Dyadic International
9. UV Flu Technologies Expands Its International Footprint
10. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
11. International Attendance for Networking and Education at Informex Beyond Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/7/2017)... WA (PRWEB) , ... October ... ... industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution ... ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C metagenome ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):